DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights

Epigenomics

Volumn 7, Issue 7, 2015, Pages 1137-1153

  Gómez, Soledad ^a   Castellano, Giancarlo ^b   Mayol, Gemma ^a   Suñol, Mariona ^c   Queiros, Ana ^b   Bibikova, Marina ^d   Nazor, Kristopher L ^e   Loring, Jeanne F ^e   Lemos, Isadora ^a   Rodríguez, Eva ^a   De Torres, Carmen ^a   Mora, Jaume ^a   Martín Subero, José I ^b,f   Lavarino, Cinzia ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

^d ILLUMINA INC   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ALK; CCND1; development; DNA methylome; neuroblastoma; non CpG sites; nonpromoter methylation

Indexed keywords

SPACER DNA; ANAPLASTIC LYMPHOMA KINASE; CCND1 PROTEIN, HUMAN; CHROMATIN; CYCLIN D1; PROTEIN TYROSINE KINASE;

ALK GENE; ARTICLE; CCND1 GENE; CHROMATIN; CONTROLLED STUDY; DNA FINGERPRINTING; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENOME; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; NEUROBLASTOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR DIFFERENTIATION; TUMOR GENE; BRAIN NEOPLASMS; CHEMISTRY; CHILD; CPG ISLAND; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; INFANT; MALE; METABOLISM; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMATIN; CPG ISLANDS; CYCLIN D1; DNA FINGERPRINTING; DNA METHYLATION; DNA, INTERGENIC; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; INFANT; MALE; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL ANALYSIS;

EID: 84937707745     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.49     Document Type: Article

References (63)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 369(9579), 2106-2120 (2007
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer. 3(3), 203-216 (2003
3. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 27(2), 289-297 (2009
4. Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307(10), 1062-1071 (2012
5. Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483(7391), 589-593 (2012
6. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45(3), 279-284 (2013
7. Sausen M, Leary RJ, Jones S, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 45(1), 12-17 (2013
8. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat. Rev. Genet. 14(3), 204-220 (2013
9. Baylin SB, Jones PA. A decade of exploring the cancer epigenome -biological and translational implications. Nat. Rev. Cancer. 11(10), 726-734 (2011
10. Dyachenko OV, Schevchuk TV, Kretzner L, Buryanov YI, Smith SS. Human non-CG methylation: are human stem cells plant-like? Epigenetics 5(7), 569-572 (2010
11. Lister R, Mukamel EA, Nery JR, et al. Global epigenomic reconfiguration during mammalian brain development. Science 341(6146), 1237905 (2013
12. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009
13. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471(7336), 68-73 (2011
14. Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaenisch R. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc. Natl Acad. Sci. USA 97(10), 5237-5242 (2000
15. Hon GC, Rajagopal N, Shen Y, et al. Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nat. Genet. 45(10), 1198-1206 (2013
16. Kreck B, Richter J, Ammerpohl O, et al. Base-pair resolution DNA methylome of the EBV-positive Endemic Burkitt lymphoma cell line DAUDI determined by SOLiD bisulfitesequencing. Leukemia 27(8), 1751-1753 (2013
17. Berman BP, Weisenberger DJ, Aman JF, et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44(1), 40-46 (2012
18. Kulis M, Queiros AC, Beekman R, Martin-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim. Biophys. Acta 1829(11), 1161-1174 (2013
19. Truong M, Yang B, Wagner J, Desotelle J, Jarrard DF. Analysis of promoter non-CG methylation in prostate cancer. Epigenomics 5(1), 65-71 (2013
20. Yang Q, Kiernan CM, Tian Y, et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin. Cancer. Res. 13(11), 3191-3197 (2007
21. Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer. Lett. 247(2), 253-258 (2007
22. Banelli B, Brigati C, Di Vinci A, et al. A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype. Lab. Invest. 92(3), 458-465 (2012
23. Asada K, Watanabe N, Nakamura Y, et al. Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas. Japanese J. Clin. Oncol. 43(6), 641-645 (2013
24. Koyama H, Zhuang T, Light JE, et al. Mechanisms of CHD5 inactivation in neuroblastomas. Clin. Cancer. Res. 18(6), 1588-1597 (2012
25. Hoebeeck J, Michels E, Pattyn F, et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer. Lett. 273(2), 336-346 (2009
26. Haruta M, Kamijo T, Nakagawara A, Kaneko Y. RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients. Cancer. Lett. 348(1-2), 167-176 (2014
27. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6(5), 529-535 (2000
28. Yanez Y, Grau E, Rodriguez-Cortez VC, et al. Two independent epigenetic biomarkers predict survival in neuroblastoma. Clin. Epigenetics 7(1), 16 (2015
29. Dreidax D, Bannert S, Henrich KO, et al. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCNamplified neuroblastomas. Hum. Mol. Genet. 23(25), 6826-6837 (2014
30. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11(8), 1466-1477 (1993
31. Lavarino C, Garcia I, Mackintosh C, et al. Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. BMC Med. Genomics 1, 36 (2008
32. Bagci O, Tumer S, Olgun N, Altungoz O. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors. Cancer Lett. 317(1), 72-77 (2012
33. Garcia I, Mayol G, Rios J, et al. A three-gene expression signature model for risk stratification of patients with neuroblastoma. Clin. Cancer Res. 18(7), 2012-2023 (2012
34. Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. Genomics 98(4), 288-295 (2011
35. Nazor KL, Altun G, Lynch C, et al. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell 10(5), 620-634 (2012
36. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res. 12(6), 996-1006 (2002
37. Roadmap Epigenomics C, Kundaje A, Meuleman W, et al. Integrative analysis of 111 reference human epigenomes. Nature 518(7539), 317-330 (2015
38. Mayol G, Martin-Subero JI, Rios J, et al. DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis. PLoS ONE 7(11), e48401 (2012
39. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20(3), 307-315 (2004
40. Garcia I, Mayol G, Rodriguez E, et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol. Cancer 9, 277 (2010
41. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 44(11), 1236-1242 (2012
42. Chan TA, Glockner S, Yi JM, et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS. Med. 5(5), e114 (2008
43. Okawa ER, Gotoh T, Manne J, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27(6), 803-810 (2008
44. Aran D, Hellman A. DNA methylation of transcriptional enhancers and cancer predisposition. Cell 154(1), 11-13 (2013
45. Guo JU, Su Y, Shin JH, et al. Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. Nat. Neurosci. 17(2), 215-222 (2014
46. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008
47. Ball MP, Li JB, Gao Y, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat. Biotechnol. 27(4), 361-368 (2009
48. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13(7), 484-492 (2012
49. Kozlenkov A, Roussos P, Timashpolsky A, et al. Differences in DNA methylation between human neuronal and glial cells are concentrated in enhancers and non-CpG sites. Nucleic Acids Res. 42(1), 109-127 (2014
50. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215), 930-935 (2008
51. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J. 416(2), 153-159 (2008
52. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455(7215), 975-978 (2008
53. Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma-preclinical and clinical advancements. Nat. Rev. Clin. Oncol. 9(7), 391-399 (2012
54. Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer. Res. 69(18), 7338-7346 (2009
55. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 3(9), 1709-1723 (2007
56. Molenaar JJ, Ebus ME, Koster J, et al. Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene 29(18), 2739-2745 (2010
57. Wang Y, Rao VK, Kok WK, et al. SUMO modification of Stra13 is required for repression of cyclin D1 expression and cellular growth arrest. PLoS ONE 7(8), e43137 (2012
58. French JD, Ghoussaini M, Edwards SL, et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am. J. Hum. Genet. 92(4), 489-503 (2013
59. Suzuki H, Yamamoto E, Maruyama R, Niinuma T, Kai M. Biological significance of the CpG island methylator phenotype. Biochem. Biophys. Res. Commun. 455(1-2), 35-42 (2014
60. GEO Expression Omnibus. http://www.ncbi.nlm.nih.gov/geo/
61. Lavarino C. DNA methylation changes at CpG and non-CpG sites are associated with development and clinical behavior in neuroblastoma. www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token
62. Lavarino C. DNA methylation changes at CpG and non-CpG sites are associated with development and clinical behavior in neuroblastoma [methylation]. http://www.ncbi.nlm.nih.gov/geo/query
63. Lavarino C. DNA methylation changes at CpG and non-CpG sites are associated with development and clinical behavior in neuroblastoma [gene expression]. http://www.ncbi.nlm.nih.gov/geo/query